

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Steven E. Cwirla, et al.)	Art Unit: 1646
)	
Application No.: 10/659,207)	Examiner: XIE, Xiaozhen
)	
Filed: September 9, 2003)	Attorney Docket No. 44368-0003 C1
)	
Title COMPOUNDS HAVING AFFINITY FOR THE)	Customer No. 25213
GRANULOCYTE-COLONY STIMULATING)	
FACTOR RECEPTOR (G-SCFR) AND		
ASSOCIATED USES		

VIA EFS – NOVEMBER 19, 2007

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language and all additional publications other than U.S. patents and U.S. patent application publications or is identified, with an asterisk (*), as having been previously cited in priority **U.S. Patent Application No.: 09/620,091, filed: July 20, 2000 (now issued U.S. Patent No. 6,716,811)**, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application,

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(c) is provided below; **or**
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 44368-0004 C1).

Respectfully submitted,
HELLER EHRMAN LLP

By: J. P. Bernhardt
Jeffery P. Bernhardt, Reg. No. 54,997

Dated: November 19, 2007

275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213